AI MARKET SCANNING

Arcus Biosciences, Inc.

🏛️ NYSE 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +1.80%
MAX GAP RECORD +13.18%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $RCUS
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 05, 2026 Earnings Release 2026-08-05 (AFTER CLOSE)
+6.14%
May 05, 2026 Earnings Release 2026-05-05 (AFTER CLOSE)
-3.99%
Feb 25, 2026 Earnings Release 2026-02-25 (AFTER CLOSE)
-1.87%
Oct 28, 2025 Earnings Release 2025-10-28 (AFTER CLOSE)
+0.60%
Aug 06, 2025 Earnings Release 2025-08-06 (AFTER CLOSE)
+5.06%
May 06, 2025 Earnings Release 2025-05-06 (AFTER CLOSE)
-8.37%
Feb 25, 2025 Earnings Release 2025-02-25 (AFTER CLOSE)
+13.18%
Nov 06, 2024 Earnings Release 2024-11-06 (AFTER CLOSE)
+2.54%

VOLATILITY & GAP BIAS

AVG GAP MOVE 4.0%
Bullish Gaps (8)
Bearish Gaps (4)
Neutral / Flat (3)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $RCUS

EXECUTIONS1 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-10-20 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 86m +17.96%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗